Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) touted safety data yesterday from the late-stage trial of its once-daily inhaled bronchodilator, revefenacin, in patients with chronic obstructive pulmonary disease.
If approved, revefenacin would be the first nebulized long-acting muscarinic antagonist on the market for COPD patients in the U.S.
Get the full story at our sister site, Drug Delivery Business News.